Valneva SE (VALN) Non-Current Debt (2020 - 2026)
Valneva SE (VALN) posted Non-Current Debt of $192.1 million for Q1 2026, up 2.32% sequentially from $187.7 million in Q4 2025, and up 13.08% YoY from $169.9 million in Q1 2025.
Valneva SE (VALN) Non-Current Debt (2020 - 2026) Analysis & Trends
Valneva SE has reported Non-Current Debt for 7 years, with the latest figure at $192.1 million in Q1 2026.
- Quarterly Non-Current Debt rose 13.08% year-over-year to $192.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $192.1 million (up 13.08% YoY) and the FY2025 annual result came in at $187.7 million, up 4.15% from the prior year.
- Non-Current Debt grew to $192.1 million in Q1 2026 per VALN's latest filing, from $187.7 million in the prior quarter.
- Over five years, Non-Current Debt peaked at $192.1 million in Q1 2026 and troughed at $53.9 million in Q1 2022.
- A 5-year average of $132.1 million and a median of $138.5 million in 2025 frame the typical range for Non-Current Debt.
- The sharpest annual moves came in 2024 and 2025: Non-Current Debt jumped 113.94% in 2024, then decreased 24.3% in 2025.
- Over 5 years, Non-Current Debt stood at $89.0 million in 2022, then jumped by 60.52% to $142.9 million in 2023, then climbed by 24.57% to $177.9 million in 2024, then advanced by 5.49% to $187.7 million in 2025, then gained by 2.32% to $192.1 million in 2026.
- According to Business Quant data, Non-Current Debt over the past three periods registered $192.1 million, $187.7 million, and $127.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 882.16 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 8.96 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Valneva SE | 618.67 Mn | 477.41 Mn | 1.86 Mn | 192.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 192.52 Mn |
| Mar 31, 2026 | 192.07 Mn |
| Dec 31, 2025 | 187.71 Mn |
| Sep 30, 2025 | 127.30 Mn |
| Jun 30, 2025 | 138.51 Mn |
| Mar 31, 2025 | 169.86 Mn |
| Dec 31, 2024 | 177.94 Mn |
| Sep 30, 2024 | 168.17 Mn |
| Jun 30, 2024 | 172.89 Mn |
| Mar 31, 2024 | 172.77 Mn |
| Dec 31, 2023 | 142.85 Mn |
| Sep 30, 2023 | 116.53 Mn |
| Jun 30, 2023 | 80.82 Mn |
| Mar 31, 2023 | 89.33 Mn |
| Dec 31, 2022 | 88.99 Mn |
| Sep 30, 2022 | 94.14 Mn |
| Jun 30, 2022 | 71.55 Mn |
| Mar 31, 2022 | 53.88 Mn |
| Dec 31, 2021 | 58.03 Mn |
| Dec 31, 2020 | 55.29 Mn |